蓝鲸新闻4月2日讯，国家药监局网站4月1日发布通告，美国施乐辉有限公司（Smith & Nephew, Inc.）因部分交锁髓内钉系统（TriGen IM Nail System，国械注进20153134228）存在生产失误，对其实施二级主动召回。通报指出，问题主要涉及个别批次产品可能存在的制造缺陷，但经评估，本次召回行动不影响中国市场在用产品的安全性与有效性。施乐辉医用产品国际贸易（上海）有限公司已按要求提交召回事件报告表，并配合监管部门开展后续核查。消费者如发现相关产品异常，可及时向使用单位或监管部门反馈。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.